Close this search box.

Clinical Trial: ALLIANCE A041501


Status: Temporarily Closed

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL

Eligible for screening study DCP 001

Temporary suspension effective May 24, 2022 due to Alliance DSMB review.

Confirmation of Tolerability Phase and slot reservation completed and study currently open to Phase III enrollment as of 06/12/2018.  See Section 4.4 for registration and randomization instructions.